Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.58 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.57 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.52 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.51 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | AGXT | P21549 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1233549 | 0.90 | MEN1 (0.66) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL21002016 | 0.84 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL21002162 | 0.84 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL29986862 | 0.84 | TAAR1 (0.71) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL10636948 | 0.83 | CHRM2 (0.58) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL8354908 | 0.83 | CHRM2 (0.62) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL2178068 | 0.83 | CHRM2 (0.54) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL226849 | 0.82 | PTGS2 (0.46) | CHRM2CHRM1CHRM3 | |
| SCHEMBL21002124 | 0.82 | TAAR1 (0.69) | CHRM2CHRM1CHRM3TAAR1MTNR1A | |
| SCHEMBL27339567 | 0.81 | CHRM2 (0.55) | CHRM2CHRM1CHRM3TAAR1MTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | GERO PTE. LTD. (SG) | 2023-02-16 | — | — | US | disclosed |
| US-5661185-A | AN ALKOXYPHENYL-ALKYLUREA COMPOUND TREATING SLEEP DISORDER | BRISTOL-MYERS SQUIBB CO. (US) | 1997-08-26 | — | — | US | disclosed |
| US-5541228-A | Melatonergic agents | BRISTOL-MYERS SQUIBB CO. (US) | 1996-07-30 | — | — | US | disclosed |
| EP-0706994-A1 | Melatonergic agents | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-17 | — | — | EP | disclosed |
| US-4618683-A | Tetrahydro-6,7-dimethoxy-1H-benz[e]isoinodolines useful in the treatment of hypertension and as sedatives | ABBOTT LABORATORIES (US) | 1986-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230047816-A1 | PFKFB3 INHIBITORS AND THEIR USES | PFKFB3, PFKFB4, PFKFB1 | CHRM2 4790/4885CHRM1 4866/4885CHRM3 4488/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.